Clinical Trial Update: A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating two doses of CHF6001 (tanimilast) as add-on therapy to maintenance triple therapy in chronic obstructive pulmonary disease with chron…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF6001 DPI (tanimilast)
• Daliresp (roflumilast)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: TERMINATED